Fig. 3: Future perspectives of PDAC early detection and diagnosis.
From: Extracellular vesicles in pancreatic cancer progression and therapies
EVs isolated from biofluid, including saliva, peripheral blood serum or plasma, pancreatic juice, and urine, provide specific exosomal protein and miRNA profiling that can distinguish PDAC patients and healthy donors. Combination of novel exosomal factors (e.g. exosomal glypican-1) and known PDAC markers, such as CA19-9 from serum, provide new strategies for earlier and more reliable PDAC diagnosis.
